Patients Willing To Pay More For Avoiding Symptoms Of GERD

Published May 17, 2013
Hamilton, ON, Canada - Gastroesophageal reflux disease (GERD) affects about 25% of the population in Western countries. Patients suffer symptoms at least monthly and five percent have daily heartburn. In the study, “Assessing the Value of Symptom Relief for Patients with Gastroesophageal Reflux Disease Treatment: Willingness to Pay Using a Discrete Choice Experiment,” published in Value in Health, researchers found that patient treatment choices for GERD were most affected by the likelihood of side effects, followed by sleeping discomfort due to GERD, daytime discomfort, dietary changes, medication cost and treatment frequency. The researchers discovered that patients were willing to pay more to reduce susceptibility of GERD side effects from moderate to mild, and to relieve several GERD symptoms. Older patients (over 65) were willing to pay less for daytime discomfort relief than those younger than 65, and women were willing to pay more to avoid sleeping discomfort than men. Lead author, Ken Deal, Ph.D., from McMaster University, states: “This information can guide physicians to select the most appropriate therapy for their individual patients, help to optimize treatment strategies, and improve treatment adherence.”

Value in Health (ISSN 1098-3015) publishes papers, concepts, and ideas that advance the field of pharmacoeconomics and outcomes research as well as policy papers to help health care leaders make evidence-based decisions. The journal is published bi-monthly and has over 8,000 subscribers (clinicians, decision makers, and researchers worldwide).

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health.

For more information: www.ispor.org

Related Stories

Rethinking Medication Adherence: A Stakeholder Blueprint

May 12, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a report from its Medication Adherence and Persistence Special Interest Group that provides valuable insights into the perspectives of key stakeholders on interventions to improve medication adherence. The report, “Stakeholders’ Perspectives on Medication Adherence Enhancing Interventions: An ISPOR Report,” was published in the May 2025 issue of Value in Health.

New Research Reveals Surprising Trends in Women's Health Economics Authorship

May 12, 2025

Value in Health, the official journal of ISPOR announced the publication of new research analyzing women's representation in authorship of papers submitted to and published in Value in Health. The report, “How Well Are Women Represented in Authorship in HEOR? An Analysis of Value in Health: An ISPOR Report,” was published in the May 2025 issue of Value in Health.

Redefining Value in Care for Alzheimer's Disease and Dementia

Apr 8, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced the publication of a special themed section of research papers that provide crucial insights into the complex health economics of Alzheimer's disease and related dementias (ADRD), offering a roadmap for future research and policy as the aging population grows and novel treatments emerge.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×